| 产品编号 | bs-1704R-PE |
| 英文名称 | Anti-PAI1/PE |
| 中文名称 | PE标记的纤溶酶原激活物抑制因子抗体 |
| 别 名 | Clade E; Endothelial plasminogen activator inhibitor; Nexin; PAI 1; PAI; PAI-1; PAI1_HUMAN; PLANH1; Plasminogen activator inhibitor 1; Plasminogen activator inhibitor type 1; Serine (or cysteine) proteinase inhibitor; Serine (or cysteine) proteinase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1; Serpin E1; Serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1; Serpin peptidase inhibitor clade E; Serpine 1; Serpine1. |
| 规格价格 | 100ul/2980元 购买 大包装/询价 |
| 说 明 书 | 100ul |
| 研究领域 | 肿瘤 心血管 细胞生物 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | (predicted: Human, Mouse, Rat, Dog, Pig, Cow, Rabbit, Sheep, ) |
| 产品应用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 43kDa |
| 性 状 | Lyophilized or Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human PAI-1 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 储 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 产品介绍 |
background: PAI1 (plasminogen activator inhibitor 1) is originally cloned from human endothelial cell (Pannekoek 1986, Ginsburg 1986) and rat hepatoma cell 3 cDNA libraries. As a member of the serpin family of serine protease inhibitors, PAI1 inhibits both tissue type plasminogen activator (tPA) and urokinase type plasminogen activator (uPA). High PAI1 levels are associated with an increased risk of thromboembolic disease while PAI1 deficiency may represent an inherited autosomal recessive bleeding disorder. Function: Serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis. Subunit: Forms protease inhibiting heterodimer with TMPRSS7. Interacts with VTN. Binds LRP1B; binding is followed by internalization and degradation. Subcellular Location: Secreted Tissue Specificity: Found in plasma and platelets and in endothelial, hepatoma and fibrosarcoma cells Post-translational modifications: Inactivated by proteolytic attack of the urokinase-type (u-PA) and the tissue-type (TPA), cleaving the 369-Arg-|-Met-370 bond. DISEASE: Plasminogen activator inhibitor-1 deficiency (PAI-1D) [MIM:613329]: A hematologic disorder characterized by increased bleeding after trauma, injury, or surgery. Affected females have menorrhagia. The bleeding defect is due to increased fibrinolysis of fibrin blood clots due to deficiency of plasminogen activator inhibitor-1, which inhibits tissue and urinary activators of plasminogen. Note=The disease is caused by mutations affecting the gene represented in this entry. Note=High concentrations of SERPINE1 seem to contribute to the development of venous but not arterial occlusions. Similarity: Belongs to the serpin family Database links: Entrez Gene: 5054 Human Entrez Gene: 18787 Mouse Omim: 173360 Human SwissProt: P05121 Human SwissProt: P22777 Mouse Unigene: 414795 Human Unigene: 713079 Human Unigene: 250422 Mouse Unigene: 29367 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. PAI-1是一种单链糖蛋白，其生理作用很多： （1）与组织型纤溶酶原激活物（tissue plasminogen activator，t-PA）形成1：1的复合物而使t-PA失活; （2）保护基底膜不被血浆来源的酶所降解; （3）保护细胞间的接触面而维持组织结构的完整性; （4）在结缔组织演变、凝血、纤溶、补体激活和炎症反应等过程中具有抑制蛋白降解作用; （5）在细胞周期中，PAI-1转录水平的变化及其在细胞内的积聚，对细胞形态的维持、细胞与其间质的粘附、细胞增殖、信号转导及基因表达等都有重要意义; |
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
